Yesterday, Amgen announced that it would launch the U.S.’s first marketed Humira-referenced biosimilar, Amjevita (adalimumab-atto), at two different list prices: $3,288 and $1,557 per 40 mg pen ...

but only for the lower concentrations (40 mg/0.8 mL or 20 mg/0.4 mL) of Humira. Most are, however, working to get interchangeable status for their biosimilars, and three of them – Organon ...